TL1A/TNFSF15 Trimer 蛋白, Human (HEK293, His-Flag)

The TL1A protein (VEGI protein), belongs to the tumor necrosis factor (TNF) family and is a receptor for TNFRSF25 and TNFRSF6B. TL1A is involved in the activation of NF-κB and C-Jun pathways, which can be used as a regulator of mucosal immunity and participate in the immune pathway of inflammatory bowel disease (IBD) pathogenesis^[1][2]. TL1A originates from endothelial cells and inhibits the proliferation of breast cancer, epithelial and myeloid tumor cells^[3]. The human TL1A protein has a transmembrane domain (36-56 a.a.) that can be cleaved into membrane-type and soluble peptide fragments. TL1A/TNFSF15 Trimer Protein, Human (HEK293, His-Flag) is the extracullar part of TL1A protein (D91-L251), produced in HEK293 cells with N-terminal His- and Flag-tag.

TL1A（肿瘤坏死因子样细胞因子1A），又称TNF配体相关分子1和血管内皮细胞生长抑制剂（VEGI），是TNFRSF25和TNFRSF6B的受体，作为粘膜免疫的调节剂，参与免疫通路参与炎症性肠病 (IBD) 的发病机制^[1]。TL1A属于肿瘤坏死因子家族，来源于内皮细胞。它是 DR3 和诱饵受体 TR6/DcR3 的配体，与 DR3 的相互作用可促进免疫反应期间 T 细胞的扩增，而 TR6 则具有相反的作用。此外，DR3 是含有死亡结构域的受体，在 T 细胞激活过程中上调。TL1A 显示出可被 TNF 和 IL-1α 诱导的表达，并在表达 DR3 的细胞系中诱导 NF-κB 激活和凋亡。同时，TL1A 作为共刺激剂，可增强 IL-2 反应性和促炎细胞因子的分泌^[2]。此外，TL1A 还可激活 c-Jun N 末端激酶。TL1A 还激活 caspase-3，导致 PARP 裂解，并抑制乳腺癌、上皮细胞和骨髓肿瘤细胞的增殖。TL1A 促进正常人成纤维细胞的增殖。这些结果表明，VEGI 作为 TNF 家族的新成员，具有与 TNF 相似的信号通路，很可能是一种多功能细胞因子^[3]。人TL1A蛋白具有2个糖基化结构域和1个跨膜结构域（36-56个氨基酸），可切割成膜型肽片段和可溶性肽片段。人类的蛋白质序列与小鼠和大鼠有很大差异，相似性分别为68.42%和70.45%。

TL1A (100 ng/mL; 15 min) interacts with TR6-Fc, results in NF-κB activation^[2].
TL1A (72-251 a.a.; 100 ng/mL; 72 h) increases IL-2 responsiveness and induces cytokine release in anti-CD3- and anti-CD28-treated T cells^[2].
TL1A (1 μg/mL; 12-24 h) induces IκB degradation in U-937 cells^[3].

TL1A (human, 72-251 a.a.; 3 mg/kg; i.v.; daily for 5 d) enhances in vivo and ex vivo splenic alloactivation in C57BL/6 mice^[2].

1.Immobilized Human TNFSF15 Trimer His at 0.5 μg/mL (100 μL/Well) on the plate. Dose response curve for Anti-TNFSF15 Antibody hFc with the EC₅₀ of 10.2-18.7 ng/mL determined by ELISA.
2.Immobilized Human TNFSF15 Trimer, His Tag at 1 μg/mL (100 μl/Well) on the plate. Dose response curve for Anti-TNFSF15 Antibody, hFc Tag with the EC₅₀ of ≤4 ng/mL determined by ELISA.
3.Measured by its binding ability in a functional ELISA. Immobilized Human TNFSF15 Trimer at 1 μg/mL (100 μL/Well) can bind Anti-TNFSF15 Antibody. The ED₅₀ for this effect is 1.985-3.112 ng/mL.

Human

HEK293

N-His;N-Flag

O95150-1 (D91-L251)

9966  [NCBI]

DGDKPRAHLTVVRQTPTQHFKNQFPALHWEHELGLAFTKNRMNYTNKFLLIPESGDYFIYSQVTFRGMTSECSEIRQAGRPNKPDSITVVITKVTDSYPEPTQLLMGTKSVCEVGSNWFQPIYLGAMFSLQEGDKLMVNVSDISLVDYTKEDKTFFGAFLL&GGGGS&DGDKPRAHLTVVRQTPTQHFKNQFPALHWEHELGLAFTKNRMNYTNKFLLIPESGDYFIYSQVTFRGMTSECSEIRQAGRPNKPDSITVVITKVTDSYPEPTQLLMGTKSVCEVGSNWFQPIYLGAMFSLQEGDKLMVNVSDISLVDYTKEDKTFFGAFLL&GGGGS&DGDKPRAHLTVVRQTPTQHFKNQFPALHWEHELGLAFTKNRMNYTNKFLLIPESGDYFIYSQVTFRGMTSECSEIRQAGRPNKPDSITVVITKVTDSYPEPTQLLMGTKSVCEVGSNWFQPIYLGAMFSLQEGDKLMVNVSDISLVDYTKEDKTFFGAFLL

Approximately 60-80 kDa due to the glycosylation.

Greater than 95% as determined by Tris-Bis PAGE.

无菌粉末

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Furfaro F, et al. TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease. Curr Drug Targets. 2021;22(7):760-769.  [Content Brief]

  [2]. Migone TS, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity. 2002 Mar;16(3):479-92.  [Content Brief]

  [3]. Haridas V, et al. VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth. Oncogene. 1999 Nov 11;18(47):6496-504.  [Content Brief]